| Literature DB >> 35685730 |
Saima Muzammil1, Rahat Andleeb2, Sumreen Hayat1, Muhammad Umar Ijaz3, Asma Ashraf2, Nimrah Zafar2, Shabana Naz2, Mubashera Shaheen2.
Abstract
The purpose of this study was to assess different in vitro biological activities such as phytochemical constituents, enzymatic antioxidant status, cytotoxicity through hemolytic activity, and antidiabetic potential of plant methanolic extract through glucose uptake by yeast cells. Further, using in silico approach by the SwissADME technique the drug-likeness rules for bioactive components were characterized, while potential interactions were identified via molecular docking of a ligand with target proteins by GOLD 5.3.0. The results showed that T. divaricata was rich in TPC and TFC, i.e., 62.32 ± 4.02 and 24.53 ± 0.61, respectively, and the cytotoxic potential was 10% towards human RBCs, while protein estimation revealed the presence of protein in the extract, which was 22.82 ± 4.6. DPPH assay in comparison with ascorbic acid and several enzymatic assays, such as CAT, SOD, and POD, showed maximum antioxidant potential, i.e.,15.9 ± 2.33%, 65.57 ± 13.4%, 3.02 ± 3.4, 15.87 ± 0.5, and 0.74 ± 0.2, respectively. Glucose uptake by yeast cells, i.e., α-amylase and α-glucosidase, showed a maximum antidiabetic potential such as 75.11 ± 1.44%, 41.81 ± 3.75%, and 35.9 ± 1.24%, respectively. Our results indicate that the methanolic extract of T. divaricata has antioxidant potential and inhibits α-amylase and α-glucosidase activity and possesses maximum antidiabetic potential. The results provide scientific proof that the medicinal plant being studied is a powerful source of natural antioxidant, antidiabetic, and medicinally significant substances. In silico study, using a molecular docking, unveiled that two compounds showed good interactions with 5kzw protein with considerable binding affinities and fulfilled docking parameters. It may conclude that T. divaricata is an important vegetable with a potent source of natural antioxidants and antidiabetic activity justifying its traditional use in green therapeutics.Entities:
Year: 2022 PMID: 35685730 PMCID: PMC9173979 DOI: 10.1155/2022/4616815
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650